Ventfort exerts tissue-specific regulatory effect оn the tissue cells of the vascular wall, it affects meta
bolic processes, reduces the severity of pathological changes in the vascular wall, reduces cholesterol
and lipoprotein levels in the blood and reduces the risk of development of а number of vascular lesions.
Cerluten has a regulatory effect on the tissue-specific cells in the brain, increases the brain’s reserve
capacity, and resistance to hypoxia.
Svetinorm has a tissue-specific regulatory effect on the liver cells, normalizes their functional activity,
and restores metabolism.
Endoluten has a tissue-specific regulatory effect on the pineal gland cells, normalizes the synthesis and
release of endogenous melatonin, which is manifested in the normalization of the nervous, endocrine,
reproductive and immune systems. It restores the lipid and carbohydrate metabolism and has anti-ath
erogenic, anti-diabetic, and anti-autoimmune effects.
The prescribed complex of peptides:
Ventfort — 2 capsules per day for 3 months.
Suprefort — 2 capsules per day for 3 months.
Cerluten — 2 capsules per day for 3 months.
Endoluten — 1 capsule per day (in the morning) for 2 months.
We measured:
• indicators of the cholesterol and lipid levels;
• indicators of blood coagulation;
• indicators of subjective evaluation of the health status.
Results
It was revealed that the application of а complex of peptide bioregulators in patients with cerebral ath
erosclerosis in the 2nd and the 3rd groups helped to improve their general health. Laboratory indicators
also improved. The most positive dynamics were observed among the patients in the 3rd group, which
were treated with а complex of four peptide medications (Тable 1).
Influence of the peptide complex on lipid metabolism and the coagula Table 1
tion system in patients with cerebral atherosclerosis
lndex Before Standard Standard Standard scheme + peptide
treatment scheme scheme + peptide complex: Ventfort, Cerluten,
complex: Ventfort, Svetinorm, Endoluten
Cerluten
Total cholesterol (mmol/1) 8.7±0.4 7.6±0.3 6.3±0.5 * 5.8±0.6 *
VLDL(mmol/1) 1.42±0.07 1.22±0.06 0.92±0.07 * 0.87±0.05 *
Triglycerides (mmol/L) 4.6±0.5 4.1±0.5 3.9±0.6 3.2±0.5 *
Triglycerides (mmol/L) 151±8 138±7 119±6 * 106±7 *
* Reliable in comparison with 1st group (standard scheme).
Seoul, South Korea 2013
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.